Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
March 02 2021 - 8:00AM
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a
biopharmaceutical company utilizing sophisticated computational
methods to design de novo protein therapeutics, today
announced that Jonathan Drachman, M.D., Chief Executive Officer,
will present a corporate overview during the H.C. Wainwright Global
Life Sciences Conference taking place March 9-10, 2021.
A pre-recorded presentation will be available for on-demand
access beginning at 7:00 am ET on Tuesday, March 9, 2021 from the
investors section of the Neoleukin website at
http://investor.neoleukin.com/events. An archived replay will also
be available on the company website for at least 30 days following
the event.
About Neoleukin Therapeutics, Inc.
Neoleukin is a biopharmaceutical company creating next
generation immunotherapies for cancer, inflammation and
autoimmunity using de novo protein design technology.
Neoleukin uses sophisticated computational methods to design
proteins that demonstrate specific pharmaceutical properties that
provide potentially superior therapeutic benefit over native
proteins. Neoleukin’s lead product candidate, NL-201, is a
combined IL-2 and IL-15 agonist designed to improve tolerability
and activity by eliminating the alpha receptor binding interface.
For more information, please visit the Neoleukin
website: www.neoleukin.com.
Safe Harbor / Forward-Looking
Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, including, but not
limited to, planned development activities and timelines, and the
therapeutic properties and potential benefits of the company’s
product candidates and de novo protein design technology.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe,"
"project," "estimate," "expect," "strategy," "future," "likely,"
"may," "should," "will" and similar references to future periods.
These statements are subject to numerous risks and uncertainties,
including risks and uncertainties related to the company’s cash
forecasts, the company’s ability to advance its product candidates,
the receipt and timing of potential regulatory submissions,
designations, approvals and commercialization of product
candidates, the timing and results of preclinical and clinical
trials, the timing of announcements and updates relating to the
company’s clinical trials and related data market conditions and
further impacts of COVID-19, that could cause actual results to
differ materially from what Neoleukin expects. Further information
on potential risk factors that could affect Neoleukin’s business
and its financial results are detailed under the heading “Risk
Factors” in documents the company files from time to time with
the Securities and Exchange Commission (SEC), and other
reports as filed with the SEC. Neoleukin undertakes no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
Contacts:
MediaJulie
Rathbun206-769-9219jrathbun@neoleukin.com
InvestorsSolebury TroutBrian
Korb646-378-2923bkorb@troutgroup.com
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Apr 2023 to Apr 2024